Cargando…

Risks and benefits of anticancer drugs in advanced cancer patients: A systematic review and meta-analysis

Background: Randomized clinical trials (RCTs) of anticancer drugs without active comparators in patients who have exhausted standard of care treatment options are debated. We aimed to quantify the safety and the efficacy of anticancer drugs in advanced cancer patients who have exhausted standard of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moreau Bachelard, Camille, Coquan, Elodie, du Rusquec, Pauline, Paoletti, Xavier, Le Tourneau, Christophe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548931/ https://www.ncbi.nlm.nih.gov/pubmed/34746718 http://dx.doi.org/10.1016/j.eclinm.2021.101130

Ejemplares similares

Impact of the timing of tumor assessments on median progression-free survival in clinical trials in advanced cancer patients
por: Samaille, T., et al.
Publicado: (2021)

Drug Development in Tissue-Agnostic Indications
por: du Rusquec, Pauline, et al.
Publicado: (2021)

Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors
por: Alcantara, Marion, et al.
Publicado: (2020)

Clinical Development of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma
por: Gougis, Paul, et al.
Publicado: (2019)

Evaluation of the relevance of the growth modulation index (GMI) from the FFCD 0307 randomized phase III trial comparing the sequence of two chemotherapeutic regimens
por: du Rusquec, P., et al.
Publicado: (2023)

Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer
por: du Rusquec, Pauline, et al.
Publicado: (2020)

Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data
por: du Rusquec, Pauline, et al.
Publicado: (2019)

Treatment with anticancer drugs for advanced pancreatic cancer: a systematic review
por: Salazar, Josefina, et al.
Publicado: (2023)

Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted Agents
por: Le Tourneau, Christophe, et al.
Publicado: (2012)

Advances in Anticancer Drug Discovery
por: Reynisson, Jóhannes
Publicado: (2021)

Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer
por: Borcoman, Edith, et al.
Publicado: (2020)

Drug–drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure
por: Raoul, J.L., et al.
Publicado: (2023)

Anticancer Drugs Compared to No Anticancer Drugs in Patients with Advanced Hepatobiliary Cancer: A Mapping Review and Evidence Gap Map
por: Requeijo, Carolina, et al.
Publicado: (2023)

The abscopal effect of immune-radiation therapy in recurrent and metastatic cervical cancer: a narrative review
por: Ollivier, Luc, et al.
Publicado: (2023)

Lack of correlation between the costs of anticancer drugs and clinical benefits in Japan
por: Satoh, Etsuko, et al.
Publicado: (2018)

Comparison of the benefits of celecoxib combined with anticancer therapy in advanced non-small cell lung cancer: A meta-analysis
por: Zhang, Wei, et al.
Publicado: (2020)

Recent Advances in Polycaprolactones for Anticancer Drug Delivery
por: Bhadran, Abhi, et al.
Publicado: (2023)

Recent Advances in Drug Repositioning for the Discovery of New Anticancer Drugs
por: Shim, Joong Sup, et al.
Publicado: (2014)

Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations
por: Jiang, Di Maria, et al.
Publicado: (2019)

A mechanically interlocked molecular system programmed for the delivery of an anticancer drug
por: Barat, Romain, et al.
Publicado: (2015)

Graph Neural Networks to Advance Anticancer Drug Design
por: Rassil, Asmaa, et al.
Publicado: (2020)

Concept of Hybrid Drugs and Recent Advancements in Anticancer Hybrids
por: Singh, Ankit Kumar, et al.
Publicado: (2022)

Patient-reported tolerability of adverse events in phase 1 trials
por: Henon, Clémence, et al.
Publicado: (2017)

Effect of Concomitant Proton Pump Inhibitors with Pazopanib on Cancer Patients: A Retrospective Analysis
por: Moreau-Bachelard, Camille, et al.
Publicado: (2022)

Clinical Benefit, Price, and Uptake for Cancer Biosimilars vs Reference Drugs in China: A Systematic Review and Meta-Analysis
por: Luo, Xingxian, et al.
Publicado: (2023)

On the benefits of self-taught learning for brain decoding
por: Germani, Elodie, et al.
Publicado: (2023)

Synergistic effects of herbal medicines and anticancer drugs: A protocol for systematic review and meta-analysis
por: Cheon, Chunhoo
Publicado: (2021)

Toxicity profiles of antibody-drug conjugates for anticancer treatment: a systematic review and meta-analysis
por: Suzuki, Yukio, et al.
Publicado: (2023)

Significant response to pralsetinib in a medullary thyroid cancer harboring double RET variants of unknown significance
por: Hescot, Ségolène, et al.
Publicado: (2022)

Benefits of Therapeutic Drug Monitoring of Vancomycin: A Systematic Review and Meta-Analysis
por: Ye, Zhi-Kang, et al.
Publicado: (2013)

Long-Term Use of Proton Pump Inhibitors in Cancer Patients: An Opinion Paper
por: Raoul, Jean-Luc, et al.
Publicado: (2022)

Advanced and Innovative Nano-Systems for Anticancer Targeted Drug Delivery
por: Tang, Lu, et al.
Publicado: (2021)

Advances in Dietary Phenolic Compounds to Improve Chemosensitivity of Anticancer Drugs
por: Bouyahya, Abdelhakim, et al.
Publicado: (2022)

Recent advances in electrochemical determination of anticancer drug 5-fluorouracil
por: Dodevska, Totka, et al.
Publicado: (2023)

Fine‐needle aspiration as an alternative to core needle biopsy for tumour molecular profiling in precision oncology: prospective comparative study of next‐generation sequencing in cancer patients included in the SHIVA02 trial
por: Dupain, Célia, et al.
Publicado: (2020)

Combinations of targeted therapies in human cancers
por: Decaudin, Didier, et al.
Publicado: (2016)

Pembrolizumab in cervical cancer: latest evidence and clinical usefulness
por: Borcoman, Edith, et al.
Publicado: (2017)

A systematic analysis of FDA-approved anticancer drugs
por: Sun, Jingchun, et al.
Publicado: (2017)

The Anticancer Drugs
por: Wilkinson, P.
Publicado: (1980)

Communication of anticancer drug benefits and related uncertainties to patients and clinicians: document analysis of regulated information on prescription drugs in Europe
por: Davis, Courtney, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g33aa8ig2lc2jhru264h7c8tk5